National Coverage Analysis (NCA)

Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

CAG-00460N

Expand All | Collapse All

Contacts

Lead Analysts
David Dolan
David.Dolan@cms.hhs.gov
410-786-3365
Lead Medical Officers
Joseph Hutter, M.D.

History of Considerations

History Title ID View the document version
Original Consideration Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease CAG-00460N You are here